BioFire Company Info & Breaking News

Nov 06, 2020

Multiplex PCR Panels for Joint Infections on the Horizon

Premium

BioFire has submitted a 39-target test to the US Food and Drug Administration. OpGen also has a test in development.

Oct 22, 2020

BioMérieux Q3 Revenues Increase 21 Percent

The firm saw 120 percent growth in the BioFire FilmArray product line driven by strong demand for a respiratory panel which can detect SARS-CoV-2.

Oct 06, 2020

BioFire Diagnostics, UMass Medical Coronavirus Tests Get FDA Emergency Use Authorization

BioFire's test is designed to detect and differentiate between SARS-CoV-2 and other respiratory pathogens, while UMass Medical's test is only for SARS-CoV-2.

Jul 09, 2020

BioMérieux Reports 62 Percent BioFire FilmArray Sales Growth in Preliminary Q2 Release

The firm expects organic revenue growth of approximately 11 percent at constant exchange rates compared to the second quarter last year.

May 19, 2020

BioMérieux's BioFire Pneumonia Panel Could Improve Care, Find Secondary Infection in COVID-19 Cases

Premium

A handful of recently published trials suggest that use of the pneumonia panel could lead to more targeted therapy delivered more quickly than standard methods.

May 04, 2020

BioMérieux's BioFire SARS-CoV-2 Respiratory Panel Wins FDA Emergency Use Authorization

The panel is designed to detect and differentiate between nucleic acids from SARS-CoV-2 and 20 other viral and bacterial respiratory pathogens.

Apr 16, 2020

BioMérieux Reports 22 Percent Q1 Revenue Growth, Withdraws Full-Year Guidance

First quarter revenue growth was driven by "unprecedented demand" for molecular biology products for use in COVID-19 testing.

Mar 24, 2020

BioMérieux Rapid Coronavirus Test Gets FDA Emergency Use Authorization

The 45-minute test was developed by BioMérieux subsidiary BioFire Defense and can be used on the company's FilmArray and FilmArray Torch systems.

Mar 20, 2020

Commercial Coronavirus Test Developers Tweak Timelines, EUA Plans in Light of Loosened FDA Guidance

Test makers are preparing to ramp up production of new SARS-CoV-2 assays and designated testing systems in anticipation of increased demand.

Mar 18, 2020

BioMérieux's BioFire Diagnostics Sued; Coronavirus Tests Accused of Infringing Theranos Patents

Labrador Diagnostics, a firm controlled by an investment group that acquired Theranos' IP, alleged BioFire's FilmArray products infringe two patents.

Menu

BioFire

Multiplex PCR Panels for Joint Infections on the Horizon

BioMérieux Q3 Revenues Increase 21 Percent

BioFire Diagnostics, UMass Medical Coronavirus Tests Get FDA Emergency Use Authorization

BioMérieux Reports 62 Percent BioFire FilmArray Sales Growth in Preliminary Q2 Release

BioMérieux's BioFire Pneumonia Panel Could Improve Care, Find Secondary Infection in COVID-19 Cases

BioMérieux's BioFire SARS-CoV-2 Respiratory Panel Wins FDA Emergency Use Authorization

BioMérieux Reports 22 Percent Q1 Revenue Growth, Withdraws Full-Year Guidance

BioMérieux Rapid Coronavirus Test Gets FDA Emergency Use Authorization

Commercial Coronavirus Test Developers Tweak Timelines, EUA Plans in Light of Loosened FDA Guidance

BioMérieux's BioFire Diagnostics Sued; Coronavirus Tests Accused of Infringing Theranos Patents

Pages

Breaking News

In Brief This Week: Quest Diagnostics, Fluidigm, BD, and More

Tempus Gets CE Mark for xT Tumor Sequencing Assay

BTIG Downgrades Fulgent Genetics from Buy to Neutral

Cepheid Receives CE Mark for SARS-CoV-2, Flu A/B, RSV Combination Test

OpGen Inks $10M Private Placement Agreement

Agilent Q4 Revenues Rise 8 Percent